Kyverna Therapeutics (KYTX) Profit After Tax (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Profit After Tax data on file, last reported at -$39.7 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 10.99% year-over-year to -$39.7 million; the trailing twelve-month figure through Mar 2026 stood at -$156.4 million (down 7.56% YoY), and the FY2025 full-year result was -$161.3 million, down 26.53% from the prior year.
• Profit After Tax for Q1 2026 stood at -$39.7 million, down from -$37.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$11.1 million in Q1 2023 and bottomed at -$44.6 million in Q1 2025.
• The 4-year median for Profit After Tax is -$34.5 million (2024), against an average of -$29.9 million.
• The widest annual swing landed in 2024, when Profit After Tax slumped 139.55%; it then increased 10.99% in 2026.
• A 4-year view of Profit After Tax shows it stood at -$20.7 million in 2023, then slumped by 81.11% to -$37.5 million in 2024, then declined by 0.83% to -$37.8 million in 2025, then slipped by 5.03% to -$39.7 million in 2026.
• The last three Profit After Tax figures came in at -$39.7 million (Q1 2026), -$37.8 million (Q4 2025), and -$36.8 million (Q3 2025), per Business Quant data.

Peer Comparison